Acute Lymphatic Leukemia

3

Review clinical trials related to Acute Lymphatic Leukemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)

In this study, we investigate the cardiopulmonary health of survivors who underwent cancer treatment for acute lymphoblastic leukemia (ALL) or lymphoma during childhood, compared with healthy controls. Modern imaging techniques (MRI, MSOT, and echocardiography) as well as questionnaires assessing cardiopulmonary and mental health are used.

Participants needed: 180
Trial details
Age: 3+Biological sex: AllType: InterventionalSponsor: University of Erlangen-Nürnberg Medical SchoolUpdated: Jul 15, 2026Locations: 1
Eligibility criteria

no cancer diagnosis [+4]

Pregnancy, Lactation [+27]

Status: Recruiting

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Participants needed: 40
Trial details
Biological sex: AllType: InterventionalSponsor: Miltenyi Biomedicine GmbHUpdated: Nov 26, 2025Locations: 7
Eligibility criteria

Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the par... [+1]

No exclusion criteria

Status: Recruiting

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT. Participants will: * Partake in exams, tests, and procedures as part of usual cancer care. * Partake in conditioning, which is the treatment that is given before a transplant. * Have a cord blood transplant. * Partake in radiation following the transplant.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Leland MethenyUpdated: Jun 4, 2025Locations: 1
Eligibility criteria

Antecedent hematological disease (e.g., myelodysplasia (MDS)) [+28]

Creatinine clearance < 50ml/min [+12]